Health & Biotech · Jun 10, 2026
Leumit: The Smallest HMO, and Why It Still MattersLeumit covers ~750,000 Israelis — the smallest of the four HMOs, and roughly the size of the population of San Francisco. Often discounted. Frequently…
Health & Biotech
27 storiesUpdated Aug 14, 2026
Latest in Health & Biotech
27 stories
Lead storyHealth & Biotech · Jul 3, 2026
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries (NYSE: TEVA) — 1901 Jerusalem roots; modern form 1976 merger under Eli Hurvitz. Copaxone: world's best-selling MS drug at peak. $40B Actavis acquisition (2016). ~$4.25B opioid settlements.…
Read →Topics
Deeper coverage tracks inside Health & Biotech
Reference and analysis
Long-form reference entries in Health & Biotech
- The IIA Budget as Industrial Policy
The Israel Innovation Authority's grant programs are the cheapest non-dilutive capital in Israel and the single clearest…
- Reichman and the Private University Question
Reichman University is Israel's only private research university and the closest analog to a Stanford-style entrepreneur…
- Yeda's Copaxone — The Best Academic License in History
The Weizmann Institute's tech transfer arm earned more than $1.5bn in royalties on a single multiple sclerosis drug. The…
- The Technion Pipeline
The Technion is the single largest source of Israeli founder formation. T3 — its tech-transfer arm — and the surrounding…
- Weizmann and the Yeda Model
Yeda — the Weizmann Institute's tech-transfer arm — is the prototype Israeli university commercialisation vehicle. Its l…
- The Israeli Hospital Innovation Engine: Sheba, Hadassah, Ichilov & the Commercial Translation Layer
- Sheba ARC: The Global Innovation Arm and Sheba Medical Center's International Position
Israeli Biotech Companies — The Olam Reference
Articles
Page 3 of 3
Health & Biotech · Jun 3, 2026
Israel's Biotech Decade Has Gone InstitutionalIsrael's biotech decade is no longer a frontier story — it's a category. $1.2 billion a year in health-tech funding, AI-native drug discovery platform…
Health & Biotech · Jun 9, 2026
Meuhedet: The Third HMO Nobody MapsMeuhedet covers ~1.3 million Israelis — ~14% of the country — and indexes heavily toward the religious, Haredi, and large-family communities growing f…
Health & Biotech · Jun 4, 2026
Israel's $25 Billion Buyer Class You Can't SeeIsrael's four HMOs control more than $25 billion in annual healthcare procurement. Their decisions on AI, pharma, diagnostics, and digital health shap…
Health & Biotech · Jun 9, 2026
The Combat-Medicine DividendIsrael's grimmest input — a long history of war injury — has become a real engine of medical innovation. It is an uncomfortable fact, and an honest ac…
Health & Biotech · Jun 6, 2026
The Hospital as Startup FactoryIsrael's most distinctive contribution to medicine is not a drug or a device. It is a model: the hospital itself turned into a co-development engine t…
Health & Biotech · May 28, 2026
Israel Builds the Tools, Not the DrugsIsrael has roughly 1,800 life-sciences companies and almost no original blockbuster drugs. That is not a gap in the ecosystem — it is the shape of it.
Health & Biotech · May 31, 2026
The Four FundsEvery Israeli belongs to one of four health funds — Clalit, Maccabi, Meuhedet, or Leumit — each one insurer and clinic and pharmacy in a single organi…
Health & Biotech · May 26, 2026
The IIA Budget as Industrial PolicyThe Israel Innovation Authority's grant programs are the cheapest non-dilutive capital in Israel and the single clearest statement of which sectors th…